Cilostazol Pharmacology

Real Life Pharmacology - Pharmacology Education for Health Care Professionals

Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist

Education, Health & Fitness, Medicine

5 • 716 Ratings

🗓️ 28 November 2019

⏱️ 12 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Cilostazol has antiplatelet and vasodilatory effects. Because of this, it can manage symptoms of intermittent claudication.

GI upset, headache, and edema are common adverse effects associated with the use of cilostazol.

Cilostazol is recommended to be given on an empty stomach.

In patients with heart failure, cilostazol use is contraindicated.

CYP3A4 interactions are prevalent with cilostazol. Inhibitors of CYP3A4 can increase the concentrations of cilostazol.

Transcript

Click on a timestamp to play from that location

0:00.0	Hey all, welcome back to the Real Life Pharmacology Podcast. Thanks so much for listening. I'm your host,
0:05.9	Eric Christensen, and you can track me down on LinkedIn as well as Real Life Pharmacology.com.
0:13.8	You can hit the contact button there, shoot us a message. Be sure you go to Real Life Pharmacology.com.
0:19.5	Snag your free 31 page PDF on the top 200 drugs.
0:24.3	I provide a lot of clinical pearls within that document.
0:28.0	So definitely go check that out.
0:29.7	Take advantage of that absolutely for free and for following the podcast here.
0:36.3	So today I'm going to cover psilostazol.
0:40.0	The brand name of this medication is pletal.
0:44.2	And from a mechanism of action standpoint, this drug inhibits the action of phosphodiasterase
0:52.8	3.
0:54.0	So you're probably wondering why is phosphodiasterase 3 important.
0:59.1	Phosphodasterase 3 breaks down cyclic AMP.
1:05.1	And when we use siloastazol, which inhibits or blocks the action of that enzyme,
1:10.8	we end up with preserving cyclic
1:13.6	AMP.
1:14.6	Cyclic AMP works to prevent platelet aggregation as well as promoting vasodilation.
1:25.6	So those two effects can be beneficial in the setting of intermittent
1:33.3	clotication typically associated with peripheral vascular disease. That is the primary use that I see
1:41.7	this medication used in clinical practice. There's a few clinical quirks and
1:47.4	pearls you definitely need to know. And I would say those clinical quirks and pearls lead to a lower
1:56.4	desire to use this medication because we've got some potential issues with drug interactions
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.